China's WuXi Drug Outsourcer Names New CFO As Revenues Rise
This article was originally published in PharmAsia News
WuXi Pharma of China has appointed a new CFO, Hao Zhou, as the company reports unexpectedly high quarterly revenue for its drug research outsourcing business
You may also be interested in...
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.